Bolt Biotherapeutics (NASDAQ:BOLT) Issues Earnings Results, Misses Expectations By $1.46 EPS

Bolt Biotherapeutics (NASDAQ:BOLT) released its quarterly earnings data on Tuesday. The company reported ($4.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.85) by ($1.46), FiscalAI reports. The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $1.50 million. Bolt Biotherapeutics had a negative net margin of 433.74% and a negative return on equity of 92.54%.

Bolt Biotherapeutics Stock Down 0.9%

Bolt Biotherapeutics stock traded down $0.05 during mid-day trading on Wednesday, reaching $4.74. 2,941 shares of the company were exchanged, compared to its average volume of 25,122. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.59 and a current ratio of 3.59. The firm has a market cap of $9.09 million, a P/E ratio of -0.27 and a beta of 1.10. Bolt Biotherapeutics has a 12-month low of $3.91 and a 12-month high of $9.25. The business has a fifty day moving average of $4.58 and a 200 day moving average of $5.14.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Monday, April 20th. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Bolt Biotherapeutics in a research note on Friday, March 13th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Bolt Biotherapeutics presently has an average rating of “Hold” and an average target price of $41.00.

Institutional Investors Weigh In On Bolt Biotherapeutics

Several institutional investors have recently bought and sold shares of BOLT. Renaissance Technologies LLC boosted its position in shares of Bolt Biotherapeutics by 92.2% in the 4th quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock worth $301,000 after purchasing an additional 26,400 shares in the last quarter. Susquehanna International Group LLP acquired a new position in shares of Bolt Biotherapeutics during the third quarter valued at about $89,000. Shay Capital LLC purchased a new position in shares of Bolt Biotherapeutics in the 3rd quarter valued at approximately $85,000. Finally, Squarepoint Ops LLC boosted its stake in Bolt Biotherapeutics by 19.8% in the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after purchasing an additional 2,448 shares in the last quarter. 86.70% of the stock is currently owned by institutional investors and hedge funds.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.